Track: 7. Industry. Resources. Environment
1. SPIC as a support mechanism for pharmaceutical manufacturers: how to attract investment without losing existing manufacturers?
2. Benefits for suppliers of drugs with high-scale local content. Is the balance between competition and industry promotion achieved?
3. State procurement: FAS and judicial control. Scope of control and the possibility of restoration of the bidder's rights.
Chairman of the Board, Association of Pharmaceutical Manufacturers of the Eurasian Economic Union
Deputy Minister of Industry and Trade of the Russian Federation
Director of the Legal Department, Ministry of Industry and Trade of the Russian Federation
Head of Social Services and Trade Control, Federal Antimonopoly Service of the Russian Federation
Head of the Private Law Disciplines Department, Institute of Legislation and Comparative Jurisprudence under the Government of the Russian Federation, Member of the Expert Council, Russian Academy of Sciences
General Director, VEROPHARM
General Counsel, GC 'GEROFARM'
Deputy Chief Legal Officer, ChemRar Group
Chairman of the Board, NP 'Union of Pharmaceutical and Biomedical Clusters'
Adviser, Egorov, Puginskyi, Afanasiev & Partners
Partner, Head of Law Services, Ernst &Young
Director of the Department of Drug Supply and Regulation of Medical Products, Ministry of Health of Russia
Commercial Director, ACTICOMP
Deputy Chairman of the Committee for Industrial Policy and Innovation of St. Petersburg
Senior Specialist in Registration and Regulatory Compliance of Commercial Activities, Russia and CIS, Merck
Deputy General Director for GR, BIOCAD
Deputy General Director for Intellectual Property, Pharmstandard PJSC